Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491866 | 0.83 | LMNA (0.51) | FAAHSIGMAR1 | |
| SCHEMBL3494616 | 0.82 | HRH3 (0.46) | FAAHCA1CA2CA4CA9 | |
| SCHEMBL3495418 | 0.81 | MAOB (0.48) | CA1CA2CA4CA9SIGMAR1 | |
| SCHEMBL4290964 | 0.79 | CA1 (0.44) | CA1CA2CA4CA9SIGMAR1 | |
| SCHEMBL26094131 | 0.78 | CA1 (0.50) | CA1CA2CA4CA9SIGMAR1 | |
| SCHEMBL26094136 | 0.78 | CA1 (0.50) | CA1CA2CA4CA9SIGMAR1 | |
| SCHEMBL4286998 | 0.77 | TP53 (0.48) | CA1CA2CA4CA9ALDH1A1 | |
| SCHEMBL4976543 | 0.77 | CA1 (0.50) | CA1CA2CA4CA9SIGMAR1 | |
| SCHEMBL20974922 | 0.77 | SIGMAR1 (0.54) | CA1CA2CA4CA9SIGMAR1 | |
| SCHEMBL3495972 | 0.77 | SIGMAR1 (0.54) | CA1CA2CA4CA9SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | FAAH 2632/4885CA1 2275/4885CA2 218/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | FAAH 2632/4885CA1 2275/4885CA2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.